HIV Flashcards

1
Q

which HIV is the most common cause of the spread of HIV

A

HIV-1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What does HIV decrease

A

number of CD4 T-lymphocytes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

what is the structure of HIV virus

A

Small RNA virus (10kb)

Retrovirus (uses reverse transcriptase to makes DNA copy of itself)

Lentivirus

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Describe HIV mutation

A

Error prone replication

Radpid viral replication

Large population sizes 10^10 new particle each day

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Describe acute HIV-1 infection

A

Detection of very high levels of virus in blood

Symptoms of acute retroviral syndrome

6-12 weeks

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

How long is the asymptomsatic period of HIV-1

A

1-15 years

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Whar are ethe key features of HIV pathogenesis

A

Hiv is inter=grated into the DNA of infected CD4 expressing cells

Hiv can spready cell to cell very easily

FINNISH FORM PPT

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Describe activation on HIV pathogenesis

A

dramativ loss of CD4 + Tcells in lymphoid tissues in Gut (GALT)

FINNISH FROM PPT

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Why does the immune response to HIV failr to clear the virus

A

Immune system generated immune response to HIV involdcing 20 %

FINNISH FROM PPT

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Why do most HIV-1 infected ppl fair to make an effective antibody response

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

what do CD8 t cells do

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

How does HIV 1 evade the CTL response

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

what are the key populations of HIV

A

Sex workers

Gay men +other men who sex with men

Transgender women

Sex worker clients + partners of groups

prisoners

Needle drug users

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Male to female HIV transmission is ______ as efficient as female to male transmission

A

2-3x

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Who is most at risk of acquiring HIV?

A

15-24 Women

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

How does HIV transmission occur in children

A

In utero

Intra partum

breast milk

1st twin most likely to be HIV+ve

17
Q

List some preventions of HIV-1 transmission.

A

Consistent condom use

Male circumcision

Treating STI’s

Microbicide gel for women

Needle and syringe exchange for IVDU’s

PReP

Treatment as prevention (TasP) (96% reduction)

18
Q

What is 95-95-95

A

The aim was to diagnose 95% of all HIV-positive individuals, provide antiretroviral therapy (ART) for 95% of those diagnosed and achieve viral suppression for 95% of those treated by 2030

19
Q

what causes the immunodeficiency from HIV

A

HIV replication in CD4 and over time decimates their population

20
Q

what are the 3 markers for HIV infection

A

Viral load

CD4 cell count

21
Q

What are the symptoms of acute/primary infection?

A

*fever
*sore throat
*headache
*mouth ulcers
*mild lymphadenopathy
*maculopapular rash
*myalgia
*weight loss

*oral thrush

22
Q

when does HIV become AIDS

A

CD4 < 200 aids definite illness

23
Q

What are the issues with a late diagnosis of HIV

A

*Increased transmission

*Increased morbidity

*Increased mortality

24
Q

what is the most common opportunistic infection in HIV

A

PCP

25
Q

what is the treatment for HIV

A

Anti virals - usually 3

26
Q

if a patient with fever, rash and non-specific symptoms comes to GP what should you do

A

Ask about sexual history

Think of HIV seroconversion

27
Q

what should you consider in a seropositive person with a headache

A

Consider an LP

28
Q

How do you avoid drug resistance in HIV

A

Good adherence and avoidance of drug interactions

29
Q
A